Effects of Prior Effective Therapy on the Efficacy of Daptomycin and Ceftriaxone for the Treatment of Community‐Acquired Pneumonia
Clinical Infectious Diseases2008Vol. 46(8), pp. 1142–1151
Citations Over TimeTop 1% of 2008 papers
Peter Pertel, Patricia Bernardo, Charles Fogarty, Peter A. Matthews, R Northland, Mark Benvenuto, Grace M. Thorne, Steven A. Luperchio, Robert D. Arbeit, Jeff Alder
Abstract
Daptomycin is not effective for the treatment of CAP, including infections caused by Streptococcus pneumoniae and Staphylococcus aureus. The observation that as little as 24 h of prior effective therapy may impact clinical outcome suggests that trials to evaluate CAP treatment may need to exclude patients who have received any potentially effective therapy before enrollment.
Related Papers
- → Experimental study of cerebrospinal fluid tumor necrosis factor-alpha release in penicillin- and cephalosporin-resistant pneumococcal meningitis treated with different antibiotic schedules(2015)8 cited
- → Comparative efficacy of levofloxacin and ceftriaxone in the treatment of community acquired pneumonia in children(2013)3 cited
- → 1975. 1 g vs. 2 g Daily Intravenous Ceftriaxone in the Therapy of Community-onset Pneumonia: A Propensity Score Analysis From a Data of Japanese Multicenter Registry(2018)1 cited
- [Community-acquired pneumonia caused by biological pathogens].(2012)
- → PHV13: COST ANALYSIS OF CEFTRIAXONE VERSUS CEFTRIAXONE PLUS MACROLIDE TREATMENT FOR PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP)(2000)